Charles River Laboratories Acquires Cognate BioServices
February 17, 2021
Charles River Laboratories agreed to acquire Cognate BioServices for approximately $875 million in cash, expanding Charles River's capabilities into the high-growth cell and gene therapy CDMO sector. Cognate, headquartered in Memphis, Tennessee with over 500 employees, will provide Charles River integrated cell and gene therapy development, testing, and CGMP manufacturing capabilities; the deal was expected to close by end of Q1 2021.
- Targets
- Cognate BioServices, Inc.
- Sellers
- EW Healthcare Partners, Medivate Partners, BlackRock, Unnamed sovereign wealth fund
- Industry
- Biotechnology
- Location
- Tennessee, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.